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We examine the hypothesized overlap of genetic architecture for Alzheimer disease (AD),
schizophrenia (SZ), and Parkinson disease (PD) through the use of polygenic risk scores
(PRSs) with the occurrence of hallucinations in PD.
Methods
We used 2 population-based studies (ParkWest, Norway, and Parkinson’s Environment and
Gene, USA) providing us with 399 patients with PDwith European ancestry and a PD diagnosis
after age 55 years to assess the associations between 4 PRSs and hallucinations after 5 years of
mean disease duration. Based on the existing genome-wide association study of other large
consortia, 4 PRSs were created: one each using AD, SZ, and PD cohorts and another PRS for
height, which served as a negative control.
Results
A higher prevalence of hallucinations was observed with each SD increase of the AD-PRS (odds
ratio [OR]: 1.37, 95% confidence interval [CI]: 1.03–1.83). This effect was mainly driven by
APOE (OR: 1.92, 95% CI: 1.14–3.22). In addition, a suggestive decrease and increase, re-
spectively, in hallucination prevalence were observed with the SZ-PRS and the PD-PRS (OR:
0.77, 95% CI: 0.59–1.01; and OR: 1.29, 95% CI: 0.95–1.76, respectively). No association was
observed with the height PRS.
Conclusions
These results suggest that mechanisms for hallucinations in PD may in part be driven by the
same genetic architecture that leads to cognitive decline in AD, especially by APOE.
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Parkinson disease (PD) is the second most common neuro-
degenerative disease worldwide after Alzheimer disease (AD).
Associated with a decreased health-related quality of life and
increased mortality, hallucinations are an important non-
motor symptom among patients with PD.1,2
Prolonged disease duration is a major risk factor for halluci-
nations, and one hypothesis is that neurodegenerative
changes are responsible for the onset of hallucinations. A well-
known disease with hallucinations is schizophrenia (SZ), al-
though hallucinations in SZ differ in characteristics from those
in PD. Furthermore, hallucinations often co-occur with cog-
nitive decline, and the genetic underpinnings of the patho-
mechanisms related to AD or SZ may be relevant.3,4
Studies aimed to identify genetic risk factors for hallucinations
reported conflicting results, as discussed in various review
articles.5–7 However, these studies tested candidate genes, and
no study has taken a comprehensive look at the genetic ar-
chitecture of SZ, AD, or PD using polygenic risk scores
(PRSs) and their association with hallucinations among pa-
tients with PD.
Here, we used existing genome-wide association study
(GWAS) results from large consortia for AD, SZ, or PD to
first create PRS. Then, we examined the hypothesized overlap
between genetic burdens for AD, SZ, and PD susceptibility
and hallucinations among patients with PD using 2 longitu-
dinal studies of PD progression.
Methods
This study combines 2 separate population-based patient
cohorts: The Parkinson’s Environment and Gene (PEG)
study and the Norwegian ParkWest (PW) study.
The PEG study began as a population-based case-control
study among residents of the Central Valley of California,
United States. The specifics of this study have been described
previously.8 In this article, we used information from the
cohort of patients with PD that was followed between 2001
and 2019. These patients with PD were clinically classified by
movement disorder neurologists as probable idiopathic PD
according to published criteria.9 See extensive information
regarding the patient recruitment in appendix e-1, links.lww.
com/NXG/A297. In total, for the PEG study, we followed
434 patients with PD who provided information about the
presence or absence of hallucinations.
The PW study is a longitudinal, population-based cohort of
patients with PD and noncases in South and West Norway.10
All patients with incident PD diagnosed between November
2004 and August 2006 were approached for this study. Pa-
tients with PD are currently under continued follow-up, and
only those with a confirmed diagnosis of PD at their latest or
final clinical visit were eligible for this study. Here, we in-
cluded data from 191 patients at baseline and 159 patients
seen at a 5-year follow-up visit.
The presence of hallucinations was assessed using the
Movement Disorder Society–Unified Parkinson Disease
Rating Scale (MDS-UPDRS) in PEG, whereas PW used the
UPDRS.11,12 The presence of hallucinations was considered
positive when a patient or caregiver indicated the presence of
illusions, hallucinations, and/or psychosis over the past week.
To achieve consistency between studies in terms of disease
duration for the assessment of hallucination, we used in-
formation provided at the first follow-up visit by PEG patients
(on average 5.7 years after diagnosis) and from the 5-year
disease duration mark for PW patients.
Genetic data
Blood samples from both studies were genotyped using a
genome-wide single nucleotide polymorphism (SNP) array.
The PEG study used the Global Screening Array (GSA;
Illumina, Inc) chip and the PW study the Illumina Infinium
OmniExpress. For pre- and post-imputation quality control,
see appendix e-1, links.lww.com/NXG/A297. Phasing was
performed using ShapeIT v2.r790,13 and the reference panel
was HRC.r1.2016.14 We imputed SNPs using the Michigan
Imputation Server, which uses Minimac3 for imputation.15
We restricted to 5,400,408 SNPs that were available in both
data sets. All quality control was performed using Plink 1.9.16
For family members with estimated kinship of 12% or more
(reflecting second-degree relatives or more closely related)
based on estimated IBD,16 one individual was randomly se-
lected to remain in the study. Fractional ancestry among all
individuals was estimated using hidden Markov modeling and
clustering (Structure 2.3.4).17 We restricted the analysis to
individuals classified as the European super-population, and in
the analysis, we adjusted using the fractional ancestry.
After quality control, 524 patients with PD, followed longi-
tudinally, had provided both genotyping and hallucination
information (390 in PEG and 133 in PW); of these, 447 were
of European descent. We then excluded 48 patients with PD
Glossary
AD = Alzheimer disease; aOR = adjusted odds ratio; CI = confidence interval;GWAS = genome-wide association study;MDS-
UPDRS = Movement Disorder Society–Unified Parkinson Disease Rating Scale; MMSE = Mini-Mental State Examination;
PD = Parkinson disease; PEG = Parkinson’s Environment and Gene; PK = ParkWest; PRS = polygenic risk score; SZ =
schizophrenia.
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who were diagnosed at or before age 55 years to exclude
potential hereditary, nonidiopathic PD leaving 399 patients
with PD.
Standard protocol approvals, registrations,
and patient consents
All study protocols regarding human subjects have been ap-
proved by their local institutional review board, and written
consent was given by all participants.
Creation of PRSs
Four weighted sum PRSs were created using PRSice 2.1.818
based on 4 distinct sets of the GWAS, i.e., using SNPs and
effect sizes found with the GWAS of AD, SZ, PD, and for
height as a negative control. Each PRS is described in detail in
appendix e-1, links.lww.com/NXG/A297. We clumped the
data to take linkage disequilibrium into account, based on an
R-squared threshold of 0.5, without a p value threshold. The
final PRS included variants that had a p value less than of 5 ×
10−8 in the previously performed GWAS. The allelic weights
were based on the effect estimates from previous large-scale
GWAS data,19–27 and for AD a large meta-analysis that spe-
cifically estimated the effect size for the APOE allele.28 The
final score for each individual in the PD progression sample
was the sum of the number of risk alleles for that individual
weighted by each β-coefficient (log of the odds ratio). Each set
of PRS values was then standardized using z-transformations.
For specific details of each PRS, please see the additional
information in appendix e-1, links.lww.com/NXG/A297.
Analysis
We performed logistic regression analysis using each PRS as a
covariate and the presence of hallucinations among patients
with PD during follow-up as the outcome. All analyses addi-
tionally included sex, fractional ancestry, age at diagnosis,
disease duration at the time of assessment for hallucinations,
and study as potential confounders through the use of a
propensity score. We restricted the analysis to those individ-
uals diagnosed after age 55 years. All analyses were performed
using SAS 9.4 (SAS Institute, Cary NC).
Sensitivity analysis
As sensitivity analyses, we also performed logistic regression
analyses with the total population, and a subpopulation di-
agnosed at or after age 60 years. In addition, we performed
logistic regression analysis adjusting for various confounders
and/or risk factors for hallucinations to further explore the
influence of potential confounding.
For the PRS, we used a genome-wide p value threshold of 5 ×
10−8. However, the p values in the GWA studies depend on the
sample size, the effect size of the allele, and the type of outcome
(continuous vs dichotomous). As this differed between the 4
GWASs, it is difficult to compare the PRSs with each other.
Therefore, as part of our sensitivity analyses, we created 4 PRSs
with the top 75 SNPs. Furthermore, we created PRSs with
different p value thresholds (1 × 10−8, 1 × 10−7, 1 × 10−6, 1 ×
10−5, and 1 × 10−4).
Moreover, we removed patients who reported illusions (or
slight to mild hallucinations among PW patients as this
study did not differentiate between illusions and halluci-
nations) to examine findings among those with formed
hallucinations only. In addition, we performed an ordinal
logistic regression to evaluate associations with severity
of hallucinations symptoms. Finally, to determine whether
these PRSs were associated with PD susceptibility as
well as hallucinations, we performed logistic regression
analysis to assess the association between the PRS with PD
status among PEG patients and controls (restricted to
European ancestry only and those diagnosed at or after age
56 years).
Data availability
Access to deidentified data related to this study will be made
available on agreement and material transfer agreements.
Requests can be made to B.R. for clinical data of PEG, to C.L.
and B.R. for genetic data of PEG, and to J. M-G. for clinical
and genetic data of the PW study.
Results
There were 281 patients with PD of European descent in PEG
and 118 in the PW study, totaling 399 patients with PD of
European ancestry. After on average 5.5 years of disease du-
ration, hallucinations were prevalent in 53 patients (13%)
during the past week at the time of their follow-up visit (table
1). Among those with hallucinations, 38 patients (72%)
reported illusions or hallucinations with insight, whereas 15
patients (28%) had severe hallucinations with loss of insight,
psychosis, or delusions.
The results of the PRS associations with hallucinations are
provided in table 2. An increase in 1 SD in the AD-PRS was
associated with a 37% increase in the odds of hallucinations
(95% confidence interval [CI]: 1.03–1.83, table 2). The
APOE-PRS of hallucinations based on APOE status alone
(summing the risks for e4 or e2 alleles) showed strong effect
estimates, i.e., we estimated a 92% increase in odds of hallu-
cinations for an increase in 1 point of theAPOE-PRS (which is
equivalent to 1APOE-e4 allele, 95%CI: 1.14–3.22). However,
the AD-PRS on exclusion of the APOE signal also showed an
association with hallucinations (adjusted odds ratio [aOR]:
1.34, 95% CI: 1.00–1.79).
The SZ-PRSwas associated with a 23% decrease in odds (95%
CI: 0.59–1.01), and every SD increase in the PD-PRS was
associated with a 29% increase in the odds for the presence of
hallucinations, but the 95% CI is wide (95% CI: 0.95–1.76).
The height PRS was not associated with hallucinations in any
of our analyses.
There was no collinearity between the 4 PRSs. When we
combined all 3 PRSs (AD, SZ, and PD-PRS) in the same
model, the effect estimates and CIs were very similar (table 2).
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Table 1 Characteristics of patients with PD of European ancestry, diagnosed after age 55 years, stratified by study
Study
TotalPEG PW
No. %/SD No. %/SD No. %/SD
No. of patients with PD 281 118 399
At baseline
Age at diagnosis 69.0 7.2 68.7 7.1 69.0 7.2
Male sex 165 58.7 73 61.9 238 59.7
Smoking status
Never smoker 159 56.6 60 50.9 219 54.9
Former smoker 120 42.7 46 39.0 166 41.6
Current smoker 2 0.7 12 10.2 14 3.5
Years of schooling 15.1 3.7 11.3 3.2 13.9 4.0
Disease characteristics at baseline
UPDRS motor score 19.2 9.9 21.5 9.3 19.9 9.8
Motor phenotype
PIGD 155 55.2 47 39.8 202 50.6
TD 80 28.5 57 48.3 137 34.3
Intermittent/combination 46 16.4 14 11.9 60 15.0
Hoehn and Yahr ≥3 32 11.6 8 6.8 40 10.1
Total levodopa dosage in mg 372 303 NA 372 303
MMSE 28.3 1.9 27.8 2.3 28.2 2.0
RBD 47 18.0 13 11.0 60 15.8
At first follow-up (PEG study) or 5-year follow-up (PW study)
Hallucinationsa 38 13.5 15 12.7 53 13.3
Hallucinationsa—severity
None 243 86.5 103 87.3 346 86.7
Slight—illusions without loss of insight 19 6.8 0 0.0 19 4.8
Mild—formed hallucinations without loss insight 14 5.0 0 0.0 14 3.5
Mild or slightb 0 0.0 5 4.2 5 1.3
Moderate—formed hallucinations with loss insight 5 1.8 9 7.6 14 3.5
Severe—delusions or paranoia 0 0.0 1 0.9 1 0.3
Disease duration 5.7 2.4 5.0 0.1 5.5 2.0
Hoehn and Yahr ≥3 72 26.8 31 26.3 103 26.6
Total levodopa dosage in mg 624 540 568 326 607 486
UPDRS motor score 24.0 12.0 27.1 13.2 24.9 12.4
MMSE score 27.9 2.5 26.2 4.4 27.4 3.2
Depressiona 112 39.9 44 37.3 156 39.1
Cognitive impairmenta 148 52.7 54 45.8 202 50.6
Anxietya 95 33.8 NA 95 33.8
Apathya 92 32.7 75 63.6 167 41.9
Abbreviations: MDS-UPDRS = Movement Disorder Society–Unified Parkinson Disease Rating Scale; MMSE = Mini-Mental State Examination; NA = not
available; PD= Parkinson disease; PEG =Parkinson’s Environment andGene; PIGD=postural instability and gait disturbance; PW=ParkWest; RBD=REMsleep
behavior disorder; TD = tremor dominant.
a These characteristics were evaluated with the (MDS)-UPDRS questionnaire. The UPDRS score was recoded to the MDS-UPDRS score, when possible.12
Patients with PD who recorded slight to moderate symptoms of each neuropsychiatric characteristic are combined in this table.
b In contrast to the MDS-UPDRS, the UPDRS questionnaire did not differentiate between illusion and hallucinations without a loss of insight.
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However, the 95% CIs for the SZ- and PD-PRS (but not the
AD-PRS) included the null.
Results sensitivity analyses
Using different subpopulation samples, the results remained
similar (table 3). The estimated effect sizes for the AD-PRS,
SZ-PRS, and APOE-PRS appeared slightly weaker in the total
sample and stronger in the subsample diagnosed at or after
age 60 years. The effect estimates for the PD-PRS and hal-
lucinations were slightly stronger in the total population.
Adjusting for cognitive status, measured with theMini-Mental
State Examination (MMSE) and assessed at the time col-
lecting hallucination information, strengthened the effect es-
timate for the AD-PRS and the PD-PRS with hallucinations
(AD-PRS: aOR 1.50, 95% CI: 1.10–2.05; PD-PRS: aOR 1.42,
95% CI: 1.01–2.00). Restricting to a population without
cognitive decline (MMSE score ≥25) limits the sample size to
only 37 patients with PD with hallucinations, but the effect
estimates were similar to those after adjustment for MMSE
(AD-PRS: aOR 1.45, 95% CI: 1.03–2.05; PD-PRS: aOR 1.56,
95% CI: 1.04–2.33). Adjusting for other risk factors did not
change the effect estimates, although adjusting for UPDRS
motor score widened the CI slightly (see table e-1, links.lww.
com/NXG/A293). In addition, when adjusting for additional
variables, especially rapid eye movement sleep behavior dis-
order and the neuropsychiatric characteristics, such as cog-
nitive decline, depression, apathy, or anxiety scores (see table
e-1), the associations between the PD-PRS and hallucinations
remained similar, but the CIs narrowed.
As another sensitivity test, we also created multiple PRSs with
various p value thresholds (table 4). Point estimates and SDs
varied only slightly for the AD-PRS, PD-PRS, SZ-PRS, and
height PRS, respectively, suggesting that a relatively small
number of SNPs selected according to genome-wide statisti-
cally significant p value thresholds suffices. Specifically, adding
SNPs by increasing the p value threshold appears to add
precision for some (e.g., AD-PRS), but not all, PRSs. In ad-
dition, when we created PRSs with the top 75 SNPs from
GWAS data, the AD-, SZ-, and PD-PRS effect estimates
remained essentially the same—albeit CIs widened—and the
height PRS remained unassociated with hallucinations
(table 4).
After removing patients with PD who reported illusions, only
29 patients with PD reported formed hallucinations. Although
this decreased statistical power, the effect estimates and CIs
remained very similar (see table e-2, links.lww.com/NXG/
A294). The effect estimates also remained very similar when
modeling the severity of hallucinations with the PRS in an
ordinal logistic regression analysis (see table e-3, links.lww.
com/NXG/A295).
Finally, we also assessed the association between each PRS
and a PD diagnosis in the PEG study, using 1,000 individuals
(484 patients with PD and 516 controls) with a diagnosis (or
interview age for controls) at or after age 56 years. The only
PRS we found to be associated with an increased risk for a PD
diagnosis was—as expected—the PD-PRS (see table e-4,
links.lww.com/NXG/A296).
Table 2 Logistic regression for the association between schizophrenia–PRS, Alzheimer disease–PRS, PD-PRS, and the
height PRS and hallucinations among 399 patients with Parkinson disease from the 2 cohorts combined
(Parkinson’s Environment and Gene and ParkWest)
No. of SNPs aOR 95% CI
Each PRS separately
Alzheimer disease 92 1.37 1.03 1.83
APOE 2 1.92 1.14 3.22
Schizophrenia 328 0.77 0.59 1.01
Parkinson disease 181 1.29 0.95 1.76
Height 12,688 1.00 0.74 1.35
Joint analysis of the 3 PRSs
Alzheimer disease 92 1.39 1.04 1.86
Schizophrenia 328 0.79 0.60 1.05
Parkinson disease 181 1.29 0.94 1.78
Abbreviations: aOR = adjusted odds ratio; CI = confidence interval; PRS = polygenic risk score.
Fifty-three patients reported hallucinations (13.3%).
PRSs were created using a p value threshold of 5 × 10−8.
The APOE-PRS is based on rs429358 and rs7412, where each apoe4 allele increases risk (β: 1.327), whereas each apoe2 allele decreases risk (β: −0.598)
compared with apoe3.
The logistic regression analyseswere adjusted for sex, fractional ethnicity, age at diagnosis, disease duration, and study through the use of a propensity score.
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Discussion
We studied whether genetic risk architecture of AD, SZ, and
PD is associated with hallucinations in patients with PD. We
identified an increase of hallucinations within the first 6 years
after a PD diagnosis that is associated with higher AD-PRS.
The AD-PRS included a strong APOE status component.
APOE regulates amyloid-beta aggregation and clearance in the
brain, as well as brain lipid transport, glucose metabolism,
neuronal signaling, neuroinflammation, and mitochondrial
function.29 An association between APOE and cognitive de-
cline among patients with PD has been established pre-
viously.30 Previous studies of genetic risk factors related to
cognitive decline, such as APOE, and hallucinations among
patients with PD have not been consistent.5–7 In our study,
the AD-PRS without APOE still shows an association with
hallucinations, suggesting that other AD-related genetic risk
variants also play a role in the occurrence of hallucinations.
Finally, when adjusting for cognitive decline, the association
between the AD-PRS and hallucinations remained and be-
came stronger, suggesting that the AD-PRS plays an in-
dependent role in the development of hallucinations.
The SZ-PRS showed a suggestive decrease in prevalence of
hallucinations. Possible explanations for this finding include,
first, that this is a chance finding; second, that we efficiently
selected out of our study all SZ-related patients with parkin-
sonism; and third, that an underlying genetically determined
SZ pathobiology leads to these opposing results. In support of
this third hypothesis, SZ and PD both involve dopaminergic
dysfunction. In SZ, one of the main hypotheses for the oc-
currence of hallucinations is an increased dopaminergic ac-
tivity in the mesolimbic system. Conversely, in patients with
PD, there is a depletion of striatal dopamine due to a loss of
dopaminergic neurons in the substantia nigra. PD treatment
aims at replacing dopaminergic activity at synapses. As
neurodegeneration progresses, dopaminergic dysfunction
may create imbalances in the circuitry that may lead to hal-
lucinations, similar to the increased dopaminergic tone in the
mesolimbic pathway that leads to hallucinations in SZ.31 We
did not see any association between the SZ-PRS and a PD
diagnosis. Together, our data suggest that the biology related
to the SZ-PRS is not related to vulnerability of dopaminergic
neurons in the SN; however, the effect of dopaminergic
treatment in the mesolimbic pathway among patients with PD
with an increased genetic risk for SZ may differ from those
without a genetic risk for SZ.
Although not formally statistically significant in the primary
analysis, when analyzing the association adjusting for rapid
eye movement sleep behavior disorder, or neuropsychiatric
characteristics (such as depression or anxiety), there appears
to be an increased prevalence of hallucinations with increasing
PD-PRS. Overall, this initial finding suggests that genetic risk
factors for PD and the neurodegenerative processes un-
derlying PD might also increase the risk for developing hal-
lucinations among patients with PD.
When studying hallucinations among patients with PD, it is
important to take PD disease duration into account because
longer duration is known to be associated with an increase in
hallucinations. Therefore, we decided to analyze the preva-
lence of hallucinations within on average about 5 years of
disease duration, when the prevalence both in the PEG and
PW study was 13%. Mortality and loss-to-follow-up in lon-
gitudinal PD studies have been shown to increase sub-
stantially after 5 years, further justifying this cutoff to
minimize survival bias.
It is difficult to assess the prevalence and onset of hallucina-
tions in PD accurately, and we had to rely on the UPDRS or
MDS-UPDRS. More extensive instruments for measuring
Table 3 Logistic regression for the association between schizophrenia–PRS, Alzheimer disease–PRS, PD-PRS, and the
height PRS and hallucinations among the total population (including those diagnosed at or before age 55 years)
and the subpopulation that was diagnosed at or after age 60 years
No of SNPs
Total population (N = 448) 60+ years (N = 354)
aOR 95% CI aOR 95% CI
Alzheimer disease 92 1.23 0.93 1.61 1.47 1.09 1.99
APOE 2 1.62 0.98 2.67 2.08 1.20 3.61
Schizophrenia 328 0.79 0.61 1.02 0.74 0.55 0.99
Parkinson disease 181 1.33 0.99 1.78 1.33 0.96 1.86
Height 12,688 1.07 0.80 1.42 0.97 0.70 1.33
Abbreviations: aOR = adjusted odds ratio; CI = confidence interval; PD = Parkinson disease; PRS = polygenic risk score.
The total population consists of 448 patients with PD, with 58 patients reporting hallucinations (13.0%). The subpopulation diagnosed at or after age 60 years
consists of 354 patients; 47 patients report hallucinations (13.2%). The PRSs were created using a p value threshold of 5 × 10−8.
The APOE-PRS is based on rs429358 and rs7412, where each apoe4 allele increases risk (β: 1.327), whereas each apoe2 allele decreases risk (β: −0.598)
compared with apoe3.
The logistic regression analyseswere adjusted for sex, fractional ethnicity, age at diagnosis, disease duration, and study through the use of a propensity score.
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hallucinations have been developed,32 but were unavailable to
us at the time we collected our data. Thus, the number of
patients with hallucinations in our studies may have been
underestimated. Also, patients might have developed hallu-
cinations after the end of our follow-up, and some patients
may have been reluctant to acknowledge the presence of
hallucinations. Because there is no indication that the genetic
score would influence this mismeasurement of the outcome
differentially, outcome misclassification is probably non-
differential, and we would expect our estimates to be biased
toward the null.
Using existing GWAS data for the creation of a PRS has
several benefits. One benefit is the large size of these
studies allowing for estimates to be precise and ensuring
that the measurement errors for the weights in the PRS are
minimized. Another benefit is that there is no need for
validation of the PRS in a separate, independent data set,
as the scores are created based on independent pop-
ulations. Previous studies have provided validation for
both the AD-PRS and SZ-PRS, whereas we validated the
association between PD-PRS and PD diagnosis in our
study.33–36
Table 4 Logistic regression for the association between the 4 PRS sets and hallucinations, using various p value
thresholds and using 75 SNPs for the PRS sets among the patients with Parkinson disease from the Parkinson’s
Environment and Gene study and ParkWest study that were diagnosed after age 55 years (N = 399)
p Value threshold No of SNPs aOR 95% CI
Different p value thresholds
Alzheimer disease 1 × 10−8 81 1.36 1.02 1.82
1 × 10−7 99 1.36 1.02 1.81
1 × 10−6 128 1.40 1.05 1.87
1 × 10−5 218 1.45 1.09 1.94
1 × 10−4 444 1.36 1.01 1.82
Schizophrenia 1 × 10−8 243 0.78 0.59 1.02
1 × 10−7 374 0.78 0.59 1.03
1 × 10−6 632 0.80 0.61 1.06
1 × 10−5 1,169 0.82 0.62 1.09
1 × 10−4 2,519 0.84 0.63 1.12
Parkinson disease 1 × 10−8 152 1.29 0.94 1.76
1 × 10−7 195 1.28 0.94 1.74
1 × 10−6 253 1.25 0.92 1.70
1 × 10−5 323 1.25 0.92 1.70
1 × 10−4 408 1.22 0.90 1.65
Height 1 × 10−8 11,282 1.01 0.75 1.36
1 × 10−7 13,417 1.01 0.75 1.37
1 × 10−6 16,351 1.04 0.77 1.40
1 × 10−5 20,478 1.06 0.78 1.43
1 × 10−4 27,284 1.06 0.78 1.44
Using the top 75 SNPs from each GWAS
Alzheimer disease 75 1.36 1.02 1.82
Schizophrenia 75 0.81 0.61 1.06
Parkinson disease 75 1.18 0.87 1.61
Height 75 0.90 0.66 1.21
Abbreviations: aOR = adjusted odds ratio; CI = confidence interval; GWAS = genome-wide association study; PRS = polygenic risk score.
The logistic regression analyseswere adjusted for sex, fractional ethnicity, age at diagnosis, disease duration, and study through the use of a propensity score.
Neurology.org/NG Neurology: Genetics | Volume 6, Number 5 | October 2020 7
In genetic studies, genetic ancestry (population stratifica-
tion) is a potentially large and commonly observed con-
founder. We restricted to individuals genetically identified as
from European descent, and additionally adjusted for frac-
tional ancestry, limiting any potential confounding in our
findings. The SZ-PRS was generated in a mixed population,
whereas the AD-PRS and PD-PRS were created with indi-
viduals from European ancestry only. Although the SZ-PRS
was based on a mixed population, it consisted mainly of
European ancestry individuals. Unfortunately, until large
GWASs in diverse ethnic populations become available, it
is impossible to develop ethnicity-stratified PRS, and it re-
mains open whether the associations we report are gener-
alizable to other ethnicities.
Hallucinations in PD appear to be associated with the
genetic architecture of AD, especially as represented by
APOE. There is some indication for potential associations
between hallucinations and the genetic architecture of SZ and
also with genetic susceptibility for PD in late-onset patients.
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